Catalysts / EYPT
Upcoming FDA decisions and readouts we track for EyePoint, each with the filing that announced it.
FreeBioList tracks 3 upcoming catalysts for EyePoint (EYPT, listed on Nasdaq). All of them concern DURAVYU (vorolanib insert) (Wet age-related macular degeneration; Diabetic macular oedema — both pivotal trials).
First on the list: the Phase 3 readout for DURAVYU (vorolanib insert) (Wet age-related macular degeneration), guided by the company to Q4 2026. The furthest-out event tracked is Q4 2027. By stage, the upcoming rows are 2 Phase 3 readouts and 1 Regulatory submission.
All 3 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: How to read a Phase 3 topline readout; NDA vs BLA: the two kinds of US drug application.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| EyePoint EYPT · Nasdaq | DURAVYU (vorolanib insert) | Wet age-related macular degeneration | Q4 2026 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
| EyePoint EYPT · Nasdaq | DURAVYU (vorolanib insert) | Wet age-related macular degeneration | H1 2027 company guidance |
Regulatory submission | Verified | 8-K exhibit 99.1 ↗ | Yes |
| EyePoint EYPT · Nasdaq | DURAVYU (vorolanib insert) | Diabetic macular oedema — both pivotal trials | Q4 2027 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList